Minaxolone

A water-soluble early 1980s Glaxo steroid anaesthetic and GABA-A neurosteroid, abandoned before registration over chronic toxicity concerns; a mechanistic and historical footnote rather than a consumer compound.

During its brief clinical evaluation minaxolone produced generally acceptable anaesthesia, but induction was frequently accompanied by excitatory phenomena (involuntary muscle movements, tremor and muscular hypertonus) resembling those seen with etomidate and other steroid anaesthetics, along with dose-dependent respiratory depression; its cardiovascular profile during induction was comparatively stable. Reported animal work placed its therapeutic index (the ratio of lethal to hypnotic dose) at roughly 4, a relatively narrow margin.

Like other candidate anaesthetics of the era it was screened for the ability to provoke malignant hyperthermia (a life-threatening hypermetabolic reaction to anaesthesia) and to precipitate acute porphyria, and its cytotoxicity toward isolated hepatocytes was examined. The decisive safety problem, however, emerged in preclinical rather than clinical testing: long-term toxicology studies in rats revealed toxicity on chronic administration, and associated concerns about genotoxicity (the capacity to damage DNA) led the sponsor to withdraw the compound before registration. Repeated dosing also produced pharmacological tolerance in animal models. Minaxolone is not an approved medicine and has no established safe human use outside the historical trials.

Minaxolone (development code CCI 12923; United States Adopted Name assigned in 1979) was synthesised by Glaxo Group Research as a water-soluble successor to Althesin, the alphaxalone and alphadolone combination introduced in 1971 whose Cremophor EL vehicle caused anaphylactoid reactions and which was eventually withdrawn. By attaching a basic 11-alpha-dimethylamino group to the neuroactive pregnane skeleton, Glaxo obtained a steroid that was soluble in water while retaining strong activity at the GABA-A receptor.

Clinical evaluation proceeded in the United Kingdom, Canada and Australia between roughly 1979 and 1982, with the first human reports appearing in the Lancet in 1979, followed by a dense cluster of pharmacokinetic, cardiovascular, respiratory and infusion studies. Development was halted in the early 1980s after long-term rodent toxicology raised safety concerns, and minaxolone never reached the market. Its programme is recalled in the anaesthesia literature as the minaxolone story, a cautionary example of a promising agent stopped by preclinical toxicity.

Minaxolone is an obscure historical footnote rather than a marketed drug or a supplement. It attracted intense but short-lived research interest around 1980 as a potential replacement for Althesin and thiopental, generating a concentrated body of pharmacokinetic and clinical publications before its abrupt discontinuation. It has no recreational, nootropic or over-the-counter use and is not available to consumers. Within pharmacology it retains value as a proof of concept, having demonstrated that a water-soluble 11-aminosteroid could preserve the neurosteroid GABA-A pharmacophore; this lesson informed later water-soluble steroid anaesthetic programmes such as Org 20599 and Org 21465, and the broader modern revival of neuroactive steroids that includes alphaxalone reformulated in cyclodextrin, ganaxolone and brexanolone.